Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Panniculitis — a group of conditions that causes painful bumps to appear under the skin — is a rare manifestation of childhood-onset systemic lupus erythematosus (cSLE) that occurs mainly ... Read more
Omalizumab — a treatment already approved for allergic asthma and chronic hives — is well-tolerated and reduces disease activity in patients with systemic lupus erythematosus (SLE), a Phase 1b ... Read more
The U.S. Food and Drug Administration has granted fast track status to baricitinib for the treatment of systemic lupus erythematosus (SLE) patients, the treatment’s developers, Eli Lilly and Incyte, announced. Fast track ... Read more
Zostavax, a live attenuated herpes zoster vaccine, is well-tolerated and causes an antibody response in patients with systemic lupus erythematosus (SLE), who have a significant risk of herpes zoster infection ... Read more
Systemic lupus erythematosus (SLE) patients with highly active disease responded well to treatment with atacicept at 150 mg each week — especially those on continuous treatment for about one ... Read more
Ustekinumab as an add-on to standard of care was seen to significantly increase the number of systemic lupus erythematosus (SLE) patients with a reduction in disease activity compared to standard ... Read more
Immune cells of the brain and spinal cord, called microglia, contribute to the cognitive deficits seen in some systemic lupus erythematosus (SLE) patients by trimming neurons in the central ... Read more
Rigel Pharmaceuticals is starting a Phase 1 study in healthy people to assess R835, a potential treatment for lupus and other autoimmune diseases. The study will evaluate the safety, tolerability, pharmacokinetics (how ... Read more
Hemogenyx Pharmaceuticals and Rockefeller University recently agreed to collaborate on developing new treatments for lupus using the biotechnology company’s humanized mouse models. Hemogenyx, which is focused on developing new, ... Read more
Pin It on Pinterest